Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU2-28P is a pseudogene that corresponds to the U2 small nuclear RNA (snRNA) family, specifically annotated as "RNA, U2 small nuclear 28, pseudogene". U2 snRNAs are components of the spliceosome, a cellular complex responsible for pre-mRNA splicing in eukaryotes[3]. However, RNU2-28P itself is a pseudogene, meaning that it is a DNA sequence similar to a gene but non-functional: it is not believed to produce functional RNA or protein products, does not participate directly in splicing, is not known to have any biological activity, and is not a therapeutic target[1]. RNU2-28P should not be confused with the genuine, functional U2 snRNA genes (such as RNU2-1 or RNU2-2), which encode catalytic RNA components of the spliceosome[2][3]. The “pseudogene” annotation indicates that RNU2-28P is not expected to play a direct role in biological processes or disease, and no known drugs, mechanisms of action, biomarkers, or safety concerns are associated with it[1]. Correction/limitation: RNU2-28P is not a bona fide gene or drug target and is often included in lists of non-functional genomic elements. If seeking a functionally relevant U2 snRNA, refer to RNU2-1 or RNU2-2, which are actively studied in the context of spliceosomal function and human disease[2]. Summary: RNU2-28P is a non-coding, non-functional pseudogene of the U2 snRNA family, not a protein, enzyme, receptor, or known therapeutic target[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U2 small nuclear 28, pseudogene (RNU2-28P).